An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
HeartBeam Granted European Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) announced the issuance of a patent for its AIMIGo™ device, which provides 12-lead ECG capability, enhancing heart attack detection. This patent, granted by the European Patent Office, covers several European countries, validating HeartBeam's innovative technology. With over 11 million new cardiovascular disease cases annually in Europe, the AIMIGo device aims to allow patients to monitor their heart health outside medical settings. The innovation supports timely diagnosis and intervention for cardiac patients.
Positive
Patent issued for AIMIGo device enhances intellectual property protection in Europe.
AIMIGo is the first consumer-friendly 12-lead ECG solution, aiding in heart attack detection.
Patent addresses a significant market need for cardiovascular monitoring.
Negative
None.
Patented Technology Provides Protection for HeartBeam AIMIGo™ Credit Card-sized Device in European Market
SANTA CLARA, Calif.--(BUSINESS WIRE)--
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced today that its patent that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo™ credit card-sized device was issued by the European Patent Office. This patent offers protection for HeartBeam’s flagship technology in multiple countries in Europe and has been validated in France, Germany, Netherlands and the United Kingdom. The innovation opens the pathway for a patient to record a set of signals using HeartBeam AIMIGo outside of a medical setting with a diagnostic synthesized 12-lead ECG immediately transmitted to a physician for review and diagnosis.
According to data from the European Society of Cardiology (ESC), more than 11 million new cases of cardiovascular disease (CVD) occur in Europe as a whole, every year, with almost 49 million people living with the disease in the EU alone at a cost as of €210 billion a year. CVD remains the leading cause of mortality and a major cause of morbidity in Europe. A 12-lead ECG is the standard of care for detecting any cardiac condition and is considered one of the essential tools for heart attack detection. No single lead ECG product currently in the marketplace is able to help diagnose a heart attack. HeartBeam’s technology will be the first and only 12-lead ECG solution that fits in a consumer’s wallet for use anytime, anywhere.
“This initial European patent strengthens our intellectual property protection for our HeartBeam AIMIGo technology offering 12-lead ECG capability as we expand our product applications to reach a variety of regions in the global marketplace,” said HeartBeam CEO and Founder Branislav Vajdic, Ph.D. “We continue to enhance our intellectual property to provide protection of our technology in priority global markets.”
The newly issued patent (No. EP3280326) expands on HeartBeam’s granted and pending core patents for remote heart attack detection. The value of the recently granted 12-lead ECG patch patent is in addressing the market need for multi-week, continuous monitoring, while the AIMIGo solution is always with the patient, long term and providing a means for timely heart attack intervention. This may increase quality of life for cardiac patients by reducing the fear of chest pain and provide added peace of mind. At the core of both products is HeartBeam’s breakthrough ability to provide a patient-friendly means of obtaining a 12-lead ECG anytime, anywhere.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI™ is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo™ is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies. For more information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our in our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
What is the recent patent granted to HeartBeam, Inc. for the AIMIGo device?
HeartBeam, Inc. received a patent for its AIMIGo device that provides 12-lead ECG capability, allowing heart health monitoring outside medical settings.
How does the AIMIGo device benefit patients with cardiovascular diseases?
The AIMIGo device enables timely heart attack detection and diagnosis, enhancing patient care and peace of mind.
What is the significance of the patent issued by the European Patent Office for HeartBeam?
The patent strengthens HeartBeam’s intellectual property protection in key European markets, supporting its growth and innovation in cardiac technology.
How many cardiovascular disease cases occur annually in Europe?
Over 11 million new cases of cardiovascular disease occur every year in Europe.
What is the main advantage of HeartBeam's AIMIGo device compared to traditional ECGs?
AIMIGo is the first 12-lead ECG solution that fits into a consumer's wallet, providing heart monitoring anytime, anywhere.
